* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Phar 236 gastrointestinal drugs
Survey
Document related concepts
Pharmacognosy wikipedia , lookup
Pharmacogenomics wikipedia , lookup
List of comic book drugs wikipedia , lookup
Compounding wikipedia , lookup
Theralizumab wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Neuropharmacology wikipedia , lookup
Discovery and development of proton pump inhibitors wikipedia , lookup
Drug discovery wikipedia , lookup
Drug design wikipedia , lookup
Prescription costs wikipedia , lookup
Transcript
H2 Blockers, PPIs, & H. pylori Treatment Betty Golightly, B.Sc.Pharmacy Clinical Pharmacist Foundation in Travel Medicine (SCIEH) Certificate in Travel Health® (ISTM) September 2010 1 As per the definition regarding bias or conflict of interest put forth in the Guidelines and Criteria for CCCEP Accreditation & as per Section 10.3, I am declaring that I have no real or potential conflict to disclose. My views and opinions are my own and do not necessarily reflect those of PTSA. 2 Review anatomy & physiology of the Gastrointestinal Tract. Recognize the pharmacology of H2 Receptor Antagonists (H2 Blockers) & Proton Pump Inhibitors (PPIs) Identify the treatments available for Helicobacter pylori infection. 3 Background Statistics Epidemiology Anatomy & physiology of the GI tract Pharmacology H2 Receptor Antagonists Proton Pump Inhibitors Helicobacter pylori Significance Treatments Q &A 4 478 million rxs dispensed in 12mnths ending Oct/09 GI/genitourinary therapeutic class rank 3rd GI anti-ulcerants 23,584,000 rxs 7.8% increase from previous yr. ~$1.4 billion Top 100 Drugs (by generic name) pantoprazole 11th rabeprazole 20th esomeprazole 25th omeprazole 28th M and Campeau, L. Rx Chart Toppers: The top prescription drugs in lansoprazole 36th Gareau, Canada. Retrieved from http://www.canadianhealthcarenetwork.ca/pharmacists/clinical/drug-info/rx-chartth toppers-the-top-prescription-drugs-in-canada-3414 ranitidine 50 5 Peptic ulcer disease (PUD) Chronic inflammatory condition characterized by ulceration of the upper GI tract where parietal cells secrete pepsin and hydrochloric acid Especially stomach & duodenum->Gastric and Duodenal Ulcers 5-10% will experience in lifetime Highest b/w 50-70 y.o. Often recurrent disease Likely due to infection with Helicobacter pylori Signs/symptoms Anorexia, n/v, belching, bloating, heartburn, epigastric pain DU-better with food intake; GU-worse with food intake Risks Factors? Adapted from Section 6-Gastrointestinal Diseases. Herfindal E and Gourley D (Eds.). Textbook of Therapeutics: Drug and Disease Management. 7th Edition. Lippincott Williams & Wilkins.USA. 2000. p.515-8 6 Tortora, G. Principles of Human Anatomy 4th Edition. Harper & Row, Publishers. New York, NY. 1986. p 582 Figure 23-1 7 Tortora, G. Principles of Human Anatomy 4th Edition. Harper & Row, Publishers. New York, NY. 1986. p 596/ figure 23-10 8 Digestion 1 Ingestion-eating Peristalsis-movement of food Digestion-chemical/mechanical breakdown of food Absorption-digested food from digestive tract Defecation-indigestible substances Stomach 2 Made up of gastric glands (gastric pits) Mucous cells-mucus Parietal cells-hydrochloric acid Chief (zymogenic) cells-pepsinogen 1 Tortora, G. Principles of Human Anatomy 4th Edition. Harper & Row, Publishers. New York, NY. 1986. p 581 2 Ibid p. 599 9 Parietal activates pepsinogen ->pepsin Intrinsic factor (Vit B12 absorption!) Acidic cells hydrochloric acid (HCl) 1 environment? Protein breakdown Iron absorption First-line of defence against microbes 1 Tortora, G. Principles of Human Anatomy 4th Edition. Harper & Row, Publishers. New York, NY. 1986. p 599-600 10 Tortora, G. Principles of Human Anatomy 4th Edition. Harper & Row, Publishers. New York, NY. 1986.p599. Figure 23-11 (c). 11 Competitively/reversibly bind H2Receptor of parietal cell Dose-dependant inhibition of gastric acid secretion Useful in treatment of: DU Benign GU Hypersecretory conditions GERD Not in H. pylori Watch for drug interactions and adverse effects Examples famotidine>nizatidine>ranitidine>cimetidine (potency) Some available OTC Herfindal E and Gourley D (Eds.). Textbook of Therapeutics: Drug and Disease Management. 7 th Edition. Lippincott 12 Williams & Wilkins.USA. 2000. p.521 generic Apotex-Dec/87 2 ??? Available-tabs(150 &300mg); injection(25mg/ml); oral solution (15mg/ml) Zantac®-Aug/99 1; LCA is 0.1800 for 150mg tabs Indications 3 & Dosages (DU & GU benign) 4 Tabs or solution=300mg qd or 150mg bid x 4wks then maintenance dose of 150mg qhs 1 PHAC Drug Product Database. Retrieved from http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=43092 2 PHAC Drug Product Database. Retrieved from http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=7427 3 AHW Drug Benefit List. Retrieved from https://idbl.ab.bluecross.ca/idbl/search.do;jsessionid=bc77d69ab3f98d04d1a76811dd21f15fae5ee2e96afdccdd0f054382408eee1a.e34Rc3qT chyKbi0LbhqObhyQchqMe0 4 Repchinsky C. CPS. The Canadian Drug Reference for Health Care Professionals. Canadian Pharmacists Association: Ottawa, Canada, 2007. p2689 13 Contraindications Sensitivity to ranitidine Drug May affect bioavailability of ketoconazole Elderly pt on both hypoglycemics & theophylline interactions sporadic drug interactions with ranitidine? sucralfate (>2grams) decreases absorption of ranitidine Side-effects Constipation Diarrhea Headache (sometimes severe) 1 Repchinsky C. CPS. The Canadian Drug Reference for Health Care Professionals. Canadian Pharmacists 14 Association: Ottawa, Canada, 2007. p 2688-9 Pepcid®-Dec/861; generic Apotex-Dec/932 Available-tabs (20 &40mg); I.V. (10mg/ml) LCA is 0.5896 for 20mg tabs (Pepcid 1.0632) 3 OTC Combos Indications 4 DU & Dosages Acute tx-40mg qhs x 4-8wks Maintenance tx-20m qhs x 6-12mnths GU (benign) Acute Tx- 40mg qhs x 4-8wks 1 PHAC Drug Product Database. Retrieved from http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=7088 2 PHAC Drug Product Database. Retrieved from http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=13583 3 AHW Drug Benefit List. Retrieved from https://idbl.ab.bluecross.ca/idbl/search.do;jsessionid=0f15f636777b4c0088a159982ac6e12a37d00b0108798255f7983b33abb18a67.e34Rc3qT chyKbi0LbhqObhyQchuQe0 4 Repchinsky C. CPS. The Canadian Drug Reference for Health Care Professionals. Canadian Pharmacists Association: Ottawa, Canada, 15 2007. p1784 Contraindications hypersensitivity to H2 receptor blockers Drug interactions None listed Side-effects-top 4 Headache (4.6%) Diarrhea (1.6%) Dizziness (1.2%) constipation(1.2%) 1 Repchinsky C. CPS. The Canadian Drug Reference for Health Care Professionals. Canadian Pharmacists Association: Ottawa, Canada, 2007. p 1784 16 Irreversibly bind to & inhibit H+/K+ ATPase (hydrogen/potassium adenosine triphosphatase enzyme) aka the gastric proton pump of the parietal cell. this is final phase in acid secretion Useful in treatment of: PUD-GU,DU, including H. pylori infection GERD Hypersecretory conditions Examples Pantoprazole, rabeprazole, lansoprazole Herfindal E and Gourley D (Eds.). Textbook of Therapeutics: Drug and Disease Management. 7th Edition. Lippincott Williams & Wilkins.USA. 2000. p.523 17 Pantoloc ®-May/001; generic Ranbaxy-Feb/082 Available as 20 & 40mg enteric-coated tablets LCA 40mg tabs 1.2135 (Pantoloc =2.1733)3 Indications & Dosages (DU, GU, H.pylori) 4 Duodenal Ulcers =40mg qam x 2 wks (+2wks) Gastric Ulcers=40mg qam x 4wks (+4wks) H. pylori associated duodenal ulcer =40mg bid x 7days + clarithromycin 500mg + amoxicillin 1000mg + clarithromycin 500mg + metronidazole 500mg 1 PHAC Drug Product Database. Retrieved from http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=65469 2 PHAC Drug Product Database. Retrieved from http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=79040 3 AHW Drug Benefit List. Retrieved from https://idbl.ab.bluecross.ca/idbl/search.do;jsessionid=2416adae22ef476bdf89f30066d8f5da3d5256f6868cb53e2674560ee83a5c99.e3 4Rc3qTchyKbi0LbhqObhyQchqMe0 4 Repchinsky C. CPS. The Canadian Drug Reference for Health Care Professionals. Canadian Pharmacists Association: Ottawa, Canada, 2007. p1721-2 18 Contraindications Sensitivity to any of the ingredients Drug interactions Warfarin? Isolated cases of INR changes-monitor INR False (+) urine screening THC tests! >3ys use=malabsorption of cyanocobalamin Side-effects-top 3 Headache (2.1%) Diarrhea (1.6%) Nausea (1.2%) 1 Repchinsky C. CPS. The Canadian Drug Reference for Health Care Professionals. Canadian 19 Pharmacists Association: Ottawa, Canada, 2007. p1721-2 Pariet ™ April/02 1; generic Novo Nov/07 2 Available as 10 & 20mg enteric-coated tabs LCA 20mg= 0.7826 (Pariet=1.3975) Indications 3 & Dosages (DU, GU, H.pylori) 4 Duodenal Ulcers=20mg qd up to 4 wks (+additional tx) Gastric Ulcers=20mg qd up to 6wks (+4wks) H. pylori associated duodenal ulcer=20mg bid x 7 days + clarithromycin 500mg + amoxicillin 1000mg 1 PHAC Drug Product Database. Retrieved from http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=67735 2 PHAC Drug Product Database. Retrieved from http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=78200 3 AHW Drug Benefit List. Retrieved from https://idbl.ab.bluecross.ca/idbl/search.do;jsessionid=2416adae22ef476bdf89f30066d8f5da3d5256f6868cb53e2674560ee83a5c99.e34Rc3qTc hyKbi0LbhqObhyQchqMe0 4 Repchinsky C. CPS. The Canadian Drug Reference for Health Care Professionals. Canadian Pharmacists Association: Ottawa, Canada, 2007. p1726 20 Contraindications Sensitivity to any of the ingredients Drug interactions Co-administration decreases ketoconazole absorption Co-administration increases digoxin levels Combination tx + clarithromycin + amoxicillin Increased rabeprazole & 14-hydroxyclarithromycin plasma levels Active against most strains of H.pylori (in vitro) Side-effects-top 2 Headache (2.8%) Diarrhea (2.6%) 1 Repchinsky C. CPS. The Canadian Drug Reference for Health Care Professionals. Canadian 21 Pharmacists Association: Ottawa, Canada, 2007. p1726-8 Prevacid®-Dec/951; generic Apotex-June/092 Available as 15 & 30mg delayed-release cap and FasTab Prevacid Fastab Nov/06 (not a benefit on the DBL) 3 LCA *15 or 30mg 1.1200 (Prevacid 2.0000)4 Indications & Dosages (DU, GU, H.pylori) 5 Duodenal Ulcers =15mg qd before breakfast x 2-4 wks (+1yr for recurrent DU) Gastric Ulcers=15mg qd before breakfast x 4-8 wks H. pylori associated duodenal ulcer=30mg bid ac x 7,10,14 days + clarithromycin 500mg + amoxicillin 1000mg 1 PHAC Drug Product Database. Retrieved from http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=18516 2 PHAC Drugse. Retrieved from http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=77919 3 PHAC Drug Product Database. Retrieved from http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=73429 4 AHW Drug Benefit List. Retrieved from https://idbl.ab.bluecross.ca/idbl/search.do;jsessionid=2416adae22ef476bdf89f30066d8f5da3d5256f6868cb53e2674560ee83a5c99.e34Rc3qTc hyKbi0LbhqObhyQchqMe0 Repchinsky C. CPS. The Canadian Drug Reference for Health Care Professionals. Canadian Pharmacists Association: Ottawa, Canada, 2007. 22 p1863-7 Contraindications Sensitivity to any of the ingredients Drug Prolonged inhibition of gastric acid secretion=theory interactions ketoconazole, ampicillin esters, iron salts, digoxin absorption Co-administration->monitor theophylline levels >2gms sucralfate decreases lansoprazole bioavailability +food=50-70% decrease in extent of absorption qam prior to breakfast Side-effects-depends on study! Headache Diarrhea Abdominal pain 1 Repchinsky C. CPS. The Canadian Drug Reference for Health Care Professionals. Canadian Pharmacists Association: Ottawa, Canada, 2007. p1863-7 23 24 Spiral shaped, Gram (-), & flagellated bacteria Found b/w gastric cell surface & overlying mucus gel layer Produces an enzyme-> urease changes urea into ammonium & bicarbonate (protective) basis for non-invasive diagnostic test Ingestion of urea labelled with carbon 13 or 14 followed by a breath test of urease activity (90-95% sensitivity) Human-to-human transmission (fecal-oral) Lower socioeconomic class & crowding=increased rates. 1 Herfindal E and Gourley D (Eds.). Textbook of Therapeutics: Drug and Disease Management. 7th Edition. Lippincott Williams & Wilkins.USA. 2000. p.518-9 25 Hp-PAC->bid x 7,10, or 14 days 1 lansoprazole 30mg+clarithromycin 500mg+amoxicillin 1g Aug/98 2; DBL (kit) 82.20003 Other PPI combinations previously sited Always remember drug interactions/side-effects of clarithromycin & amoxicillin Success rates? 1 Repchinsky C. CPS. The Canadian Drug Reference for Health Care Professionals. Canadian Pharmacists Association: Ottawa, Canada, 2007. p1088 2 PHAC Drug Product Database. Retrieved from http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=61948 3 AHW Drug Benefit List. Retrieved from https://idbl.ab.bluecross.ca/idbl/search.do;jsessionid=2416adae22ef476bdf89f30066d8f5da3d5256f6868cb53e2674560ee83a5c99.e34Rc3qTc hyKbi0LbhqObhyQchqMe0 26 Recent study looking at Hybrid Therapy 1 Combination of sequential & concomitant treatments Esomeprazole 40mg + amoxicillin 1000mg (EA) bid x 7 days.... EA+ clarithromycin 500mg + metronidazole 500mg bid x 7days 97.4% eradications rates (vs. 91.9% for sequential tx) 1 Helwick, C. Hybrid therapy tops for H. Pylori infection. Retrieved from http://www.canadianhealthcarenetwork.ca/pharmacists/clinical/health-index-therapeutics/gastroenterology/hybrid-therapy-topsfor-h-pylori-infection-5258 27 28